...
首页> 外文期刊>International journal of infectious diseases : >Safety of pentavalent DTaP-IPV/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017
【24h】

Safety of pentavalent DTaP-IPV/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017

机译:PentAvalent DTAP-IPV / HIB组合疫苗在中国广州市,2011年至2017年营销后监测中的疫苗

获取原文

摘要

Background The DTaP-IPV/Hib combination vaccine can replace the acellular tetanus vaccine, polio vaccine, and the Haemophilus influenzae type B vaccine. Data on the safety of DTaP-IPV/Hib vaccines are required. We aimed to evaluate the safety of the vaccination program. Methods Using the National Adverse Events Following Immunization (AEFI) surveillance system (CNAEFIS) in Guangzhou, China, a retrospective study was performed from May 11, 2011, to December 31, 2017. There were 376 cases of adverse events after vaccination with the DTaP IPV/Hib vaccine. The primary analysis indicators were the number of vaccines used, the number of AEFI reports received, and the reporting rate (per 100,000). Results From May 1, 2011, to December 31, 2017, 516,000 doses of vaccine were inoculated, and 376 cases of adverse reactions were reported; the reporting rate was 72.8 per 100,000 vaccines. There were eight cases of serious AEFIs (1.5 per 100,000), with four cases of thrombocytopenic purpura (0.8 per 100,000); three cases of cyanosis of the lips, stiffness, and flexion of limbs, and convulsions (0.6 per 100,000); and one case of a high fever (0.2 per 100,000). The highest incidence of AEFIs occurred after the fourth dose (n = 207, 55.0%, 40.1 per 100,000), followed by the first dose (n = 81, 21.5%, 15.7 per 100,000), second dose (n = 48, 12.8%, 9.3 per 100,000) and third dose (n = 40, 10.6%, 7.7 per 100,000). The AEFI incidence was higher after injection of the vaccine into the deltoid muscle of the upper arm (n = 276, 73.4%, 53.5 per 100,000) than after injection of the vaccine into the thigh (n = 100, 26.6%, 19.4 per 100,000). There was a significant difference between AEFIs after injection into the deltoid of the upper arm deltoid and the thigh ( x2 = 164.8, P 0.05). Conclusions Most of the reported AEFIs after DTaP-IPV/Hib vaccination are not serious. There were four cases of TP in this study; vaccination may be a rare cause of thrombocytopenic purpura.
机译:背景技术DTAP-IPV / HIB组合疫苗可以代替无细胞破伤风疫苗,脊髓灰质炎疫苗和嗜血杆菌流感B型疫苗。有关DTAP-IPV / HIB疫苗的安全的数据是必需的。我们旨在评估疫苗接种计划的安全性。方法采用免疫(AEFI)监测系统(CNAEFIS)在中国广州,中国广州的监督系统(CNAEFIS),从2011年5月11日至2017年12月31日进行了回顾性研究。随着DTAP接种疫苗后有376例不良事件IPV / HIB疫苗。主要分析指标是使用的疫苗数量,收到的AEFI报告数量以及报告率(每10万人)。结果2011年5月1日至2017年12月31日,接种了516,000剂疫苗,报告了376例不良反应;报告率为每10万疫苗72.8。有八种严重的AEFIS(1.5每10万),血小板减少紫癜四种患者(每100万0.8);三种紫绀的唇膜,僵硬和肢体屈曲,以及抽搐(0.6每100,000);和一个高烧的一个案例(每100,000000.2)。在第四剂量(n = 207,每100,000)后发生最高发射率(n = 207,010.1),其次是第一剂(n = 81,21.5%,每100,000,每100,000),第二剂(n = 48,12.8%) ,9.3天/ 100,000)和第三剂量(n = 40,10.6%,每100,000.7.7)。将疫苗注入上臂的三角肌(N = 276,01010,0100,000)中的疫苗后,AEFI发病率高于将疫苗注入大腿(n = 100,010,0100,000)后(n = 100,26.6%) )。注射到上臂三角肌和大腿倍细剂后的AEFIS之间存在显着差异(X2 = 164.8,P <0.05)。结论DTAP-IPV / HIB疫苗接种后的大部分报告的AEFIS并不严重。本研究中有四种TP;疫苗接种可能是血小板减少紫癜的罕见原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号